hVIVOOPORF +27.29%43 FCF Margin % is -34.29% as of Dec. 2025. GuruFocus rates OPORF with a GF Score™ of 43/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, hVIVO ranks worse than 73.04% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. hVIVO's Free Cash Flow for the
six
months ended in Dec. 2025 was $-10.37 Mil. hVIVO's Revenue for the
six
months ended in Dec. 2025 was $30.23 Mil. Therefore, hVIVO's FCF Margin % for the quarter that ended in Dec. 2025 was -34.29%.
The historical rank and industry rank for hVIVO's FCF Margin % or its related term are showing as below:
OPORF'
s FCF Margin % Range Over the Past 10 Years
Min: -82.62 Med: -0.47 Max: 30.16
Current: -33.88
During the past 13 years, the highest FCF Margin % of hVIVO was 30.16%. The lowest was -82.62%. And the median was -0.47%.
OPORF's FCF Margin % is ranked worse than 73.04% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs OPORF: -33.88
hVIVO FCF Margin % Related Terms
hVIVO FCF Margin % Historical Data
* Premium members only.
The historical data trend for hVIVO's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, hVIVO's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's FCF Margin % distribution charts can be found below:
* The bar in red indicates where hVIVO's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO (OPORF) has a FCF Margin % of -34.29% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on hVIVO and its competitors. According to the industry distribution chart, hVIVO ranks #149 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 73%.
Is hVIVO's FCF Margin % too high?
hVIVO's current FCF Margin % is -34.29%. Based on the distribution chart, hVIVO ranks #149 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, hVIVO has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #149 out of 204 companies for FCF Margin %. This places hVIVO in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on hVIVO and its competitors. hVIVO's current FCF Margin % is -34.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current FCF Margin % is -34.29%. hVIVO's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For hVIVO (OPORF), the current FCF Margin % is -34.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
FCF Margin %: -34.29%
GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score
Get the complete analysis for OPORF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
